<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04159766</url>
  </required_header>
  <id_info>
    <org_study_id>NLY01-D1</org_study_id>
    <nct_id>NCT04159766</nct_id>
  </id_info>
  <brief_title>A Study With NLY01 in Subjects With Type 2 Diabetes</brief_title>
  <official_title>A Phase 2a Dose-Finding Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NLY01, a PEGylated Exenatide, When Administered as a Single Dose in Subjects With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neuraly, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neuraly, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2a study designed to assess the effect of NLY01 in patients with type 2
      diabetes. Patients will be monitored for safety, pharmacokinetics, and pharmacodynamic
      effects on glycemic control.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 16, 2019</start_date>
  <completion_date type="Anticipated">September 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Treatment Emergent Adverse Events</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Incidences of Adverse Events</measure>
    <time_frame>35 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma glucose</measure>
    <time_frame>24 hours</time_frame>
    <description>Change of fasting glucose profiles</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in serum insulin</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in 24 hour serum insulin</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in plasma glucagon</measure>
    <time_frame>24 hours</time_frame>
    <description>Change in 24 hour plasma glucagon concentrations</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type2 Diabetes</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>NLY01 (2.5 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NLY01 (5.0 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>NLY01 (10 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NLY01</intervention_name>
    <description>NLY01, a PEGylated form of the anti-diabetic peptide exenatide</description>
    <arm_group_label>NLY01 (10 mg)</arm_group_label>
    <arm_group_label>NLY01 (2.5 mg)</arm_group_label>
    <arm_group_label>NLY01 (5.0 mg)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subject with type 2 diabetes for at least one year

          -  Willing to continue treatment with metformin at the same dose and frequency until and
             (if applicable) to pause any treatment with a second oral antidiabetic

          -  Body Mass Index (BMI) 22.0 to 35.0 kg/m^2,

        Exclusion Criteria:

          -  History of multiple and/or severe allergies to drugs or foods or a history of severe
             anaphylactic reaction.

          -  Any history or presence of clinically relevant comorbidity (with the exception of
             conditions associated with diabetes mellitus), that may place the subject at increased
             risk as determined by the investigator

          -  Any prior exposure to an exenatide-based product (BYETTA and BYDUREON)

          -  History of gastroparesis

          -  History of severe hypoglycemia in the past 6 months

          -  If female, pregnant or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dan Lee</last_name>
    <role>Study Director</role>
    <affiliation>Neuraly, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute fur Stoffwechselforschung GmbH</name>
      <address>
        <city>Neuss</city>
        <zip>D-41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Profil Institute</name>
      <address>
        <city>Neuss</city>
        <zip>D-41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>November 6, 2019</study_first_submitted>
  <study_first_submitted_qc>November 8, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2019</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

